HRTX vs. ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, OCUL, GPCR, and IOVA
Should you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Heron Therapeutics vs.
ANI Pharmaceuticals (NASDAQ:ANIP) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.
In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Heron Therapeutics. MarketBeat recorded 8 mentions for ANI Pharmaceuticals and 3 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.78 beat ANI Pharmaceuticals' score of 1.04 indicating that Heron Therapeutics is being referred to more favorably in the news media.
Heron Therapeutics received 228 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 68.83% of users gave Heron Therapeutics an outperform vote while only 64.46% of users gave ANI Pharmaceuticals an outperform vote.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 5.8% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ANI Pharmaceuticals currently has a consensus price target of $79.75, indicating a potential upside of 20.23%. Heron Therapeutics has a consensus price target of $5.67, indicating a potential upside of 141.13%. Given Heron Therapeutics' higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
ANI Pharmaceuticals has a net margin of -1.28% compared to Heron Therapeutics' net margin of -20.31%. ANI Pharmaceuticals' return on equity of 15.87% beat Heron Therapeutics' return on equity.
ANI Pharmaceuticals has higher revenue and earnings than Heron Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
ANI Pharmaceuticals and Heron Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Heron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Heron Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HRTX) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy HRTX Stock Free HRTX Stock Alerts